Bowhead Specialty Holdings, Inc. (BOW)

NYSEFinancialsInsurance - Property & CasualtySnapshot 2026-10-23

$34.04-0.18%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Bowhead Specialty Holdings, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.2%

+10% or more+5%0%−5%−10% or less

2.44 → 2.43 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	266.79M
EPS	—	0.542
Annual ending 2026-12-31
Revenue	—	1.06B
EPS	—	2.006
Annual ending 2027-12-31
Revenue	—	1.25B
EPS	—	2.432

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain EPS guidance at $0.48 for 2026	The company maintains EPS guidance at $0.48 for 2026, supported by strong Q1 net income.	Intact	EPS falls below $0.45 in FY26	Diluted EPS: $0.48 per share FY2026-Q2; GAAP. Published target: EPS >= $0.48. Target period is not explicitly aligned with this observation. Source published Aug 3, 20260.48 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ff581d88-8a14-4e16-a6a5-e6333bb4510e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Diluted EPS was $0.48 in both 2026-Q1 and 2026-Q2, matching the full-year guidance of $0.48. Management has maintained this EPS target consistently, and the financial results are delivering in line with this guidance. Delivery assessment Oct 24, 2026
Achieve 20% growth in Gross Written Premiums (GWP) in 2026	Bowhead Specialty Holdings aims for 20% growth in gross written premiums in 2026.	Intact	GWP growth falls below 15% YoY in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross written premiums grew from $174.8 million in 2025-Q1 to $297.9 million in 2026-Q2, a 28.2% increase year-over-year in Q2. Management has consistently emphasized 20% GWP growth in 2026, and the trajectory is delivering above that target. Delivery assessment Oct 24, 2026
Enhance reinsurance agreements to support growth and risk management	A supporting condition in Bowhead Specialty Holdings, Inc.'s published investment case. The stated target is Maintain or improve reinsurance terms supporting growth.	Improving	Material weakening or termination of key reinsurance agreements	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 3 quarters. Management amended the quota share reinsurance agreement in 2026-Q2 and discussed reinsurance impacts on expense ratios in 2026-Q1. This shows ongoing focus on reinsurance agreements with moderate progress. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.43

$2.41 → $2.43 · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.41	Unavailable	7 / 4
2026-07-25	$2.41	Unavailable	7 / 4
2026-07-26	$2.41	Unavailable	7 / 4
2026-07-27	$2.41	Unavailable	7 / 4
2026-07-28	$2.41	Unavailable	7 / 4
2026-07-29	$2.41	Unavailable	7 / 4
2026-07-30	$2.41	Unavailable	7 / 4
2026-07-31	$2.41	Unavailable	7 / 4
2026-08-01	$2.39	Unavailable	5 / 4
2026-08-02	$2.41	Unavailable	7 / 4
2026-08-03	$2.41	Unavailable	7 / 4
2026-08-04	$2.41	Unavailable	7 / 4
2026-08-05	$2.42	Unavailable	7 / 4
2026-08-06	$2.42	Unavailable	7 / 4
2026-08-07	$2.41	Unavailable	5 / 4
2026-08-08	$2.42	Unavailable	7 / 4
2026-08-09	$2.42	Unavailable	7 / 4
2026-08-10	$2.42	Unavailable	7 / 4
2026-08-11	$2.42	Unavailable	7 / 4
2026-08-12	$2.42	Unavailable	7 / 4
2026-08-13	$2.41	Unavailable	5 / 4
2026-08-14	$2.41	Unavailable	5 / 4
2026-08-15	$2.41	Unavailable	5 / 4
2026-08-16	$2.41	Unavailable	5 / 4
2026-08-17	$2.41	Unavailable	5 / 4
2026-08-18	$2.41	Unavailable	5 / 4
2026-08-19	$2.41	Unavailable	5 / 4
2026-08-20	$2.42	Unavailable	5 / 4
2026-08-21	$2.44	Unavailable	5 / 4
2026-08-22	$2.44	Unavailable	5 / 4
2026-08-23	$2.44	Unavailable	5 / 4
2026-08-24	$2.44	Unavailable	5 / 4
2026-08-25	$2.44	Unavailable	5 / 4
2026-08-26	$2.44	Unavailable	5 / 4
2026-08-27	$2.44	Unavailable	5 / 4
2026-08-28	$2.44	Unavailable	5 / 4
2026-08-29	$2.44	Unavailable	5 / 4
2026-08-30	$2.44	Unavailable	5 / 4
2026-08-31	$2.44	Unavailable	5 / 4
2026-09-01	$2.44	Unavailable	5 / 4
2026-09-02	$2.44	Unavailable	5 / 4
2026-09-03	$2.44	Unavailable	5 / 4
2026-09-04	$2.44	Unavailable	5 / 4
2026-09-05	$2.44	Unavailable	5 / 4
2026-09-06	$2.44	Unavailable	5 / 4
2026-09-07	$2.44	Unavailable	5 / 4
2026-09-08	$2.44	Unavailable	5 / 4
2026-09-09	$2.44	Unavailable	5 / 4
2026-09-10	$2.44	Unavailable	5 / 4
2026-09-11	$2.44	Unavailable	5 / 4
2026-09-12	$2.44	Unavailable	5 / 4
2026-09-13	$2.44	Unavailable	5 / 4
2026-09-14	$2.44	Unavailable	5 / 4
2026-09-15	$2.44	Unavailable	5 / 4
2026-09-16	$2.44	Unavailable	5 / 4
2026-09-17	$2.44	Unavailable	5 / 4
2026-09-18	$2.44	Unavailable	5 / 4
2026-09-19	$2.44	Unavailable	5 / 4
2026-09-20	$2.44	Unavailable	5 / 4
2026-09-21	$2.44	Unavailable	5 / 4
2026-09-22	$2.44	Unavailable	5 / 4
2026-09-23	$2.44	Unavailable	5 / 4
2026-09-24	$2.44	Unavailable	5 / 4
2026-09-25	$2.44	Unavailable	5 / 4
2026-09-26	$2.44	Unavailable	5 / 4
2026-09-27	$2.44	Unavailable	5 / 4
2026-09-28	$2.44	Unavailable	5 / 4
2026-09-29	$2.44	Unavailable	5 / 4
2026-09-30	$2.44	Unavailable	5 / 4
2026-10-01	$2.44	Unavailable	5 / 4
2026-10-02	$2.44	Unavailable	5 / 4
2026-10-03	$2.44	Unavailable	5 / 4
2026-10-04	$2.44	Unavailable	5 / 4
2026-10-05	$2.44	Unavailable	5 / 4
2026-10-06	$2.44	Unavailable	5 / 4
2026-10-07	$2.44	Unavailable	5 / 4
2026-10-08	$2.44	Unavailable	5 / 4
2026-10-09	$2.44	Unavailable	5 / 4
2026-10-10	$2.44	Unavailable	5 / 4
2026-10-11	$2.44	Unavailable	5 / 4
2026-10-12	$2.44	Unavailable	5 / 4
2026-10-13	$2.44	Unavailable	5 / 4
2026-10-14	$2.44	Unavailable	5 / 4
2026-10-15	$2.43	Unavailable	5 / 4
2026-10-16	$2.43	Unavailable	5 / 4
2026-10-17	$2.43	Unavailable	5 / 4
2026-10-18	$2.43	Unavailable	5 / 4
2026-10-19	$2.43	Unavailable	5 / 4
2026-10-20	$2.43	Unavailable	5 / 4
2026-10-21	$2.43	Unavailable	5 / 4
2026-10-22	$2.43	Unavailable	5 / 4
2026-10-23	$2.43	Unavailable	5 / 4
2026-10-24	$2.43	Unavailable	5 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	2
2026-06-01	5	2
2026-07-01	5	2
2026-08-01	5	5
2026-09-01	2	6
2026-10-01	1	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain EPS guidance at $0.48 for 2026Diluted EPS: $0.48 per share
Achieve 20% growth in Gross Written Premiums (GWP) in 2026Direct metric needs a verified mapping
Enhance reinsurance agreements to support growth and risk managementQualitative condition

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.2%Typical daily move · historical

Downside history

-26.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bowhead Specialty Holdings, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

BOW is a growth-oriented financial company, with a long-term thesis built on expanding gross written premiums and maintaining earnings guidance. The thesis is intact, but confidence has eased from high to medium, and the next few quarters will test whether growth and earnings stay on track.

What's priced into Bowhead Specialty Holdings, Inc.

BOW trades at a 1.3-times premium to peers, which the evidence describes as a durable premium; the valuation is expensive. The expectations gap is negative at 0.13, while the priced-in assessment is tagged justified and fragility is low, so the valuation appears to assume continued strong execution without signs of concentrated fragility.

What the fundamentals likely do

Near term, gross written premiums grew 28.2% year over year in 2026 Q2, above management’s stated 20% growth priority, and diluted EPS matched the full-year guidance in both Q1 and Q2. Reinsurance work shows moderate progress, while a guidance cut, the smaller-company miss risk, and the recent litigation filing remain risks; the sector backdrop is a headwind.

What Bowhead Specialty Holdings, Inc. hinges on

The multi-year thesis hinges on sustaining premium growth and keeping earnings guidance intact, while making further progress on reinsurance. Near term, a guidance cut would be a meaningful negative, and falling rates could weigh on the financial sector; continued earnings strength and higher guidance from sector bellwethers would support sector momentum.